Determination of Antiviral Drug, Favipiravir by a Stability-indicating Chromatographic Method
Open Access
- 27 June 2024
- journal article
- research article
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 40 (3) , 673-680
Abstract
To determine favipiravir in bulk and marketed formulation, a stability-indicating reversed-phase high performance liquid chromatographic approach has been established that was proved to be sensitive and accurate. SPOLAR C18 column with 250 mm x 4.6 mm, 5 μ dimensions, 0.1% ortho-phosphoric acid buffer: acetonitrile in 50:50 as a mobile phase at 30 °C were used to achieve the chromatographic separation. The retention time of 2.613 min was recorded, when favipiravir measured at 323 nm using 1 mL/min flow rate. The suitable chromatographic conditions were identified through optimization studies. The method showed appreciable linearity (R2 = 0.999) over 10-60 µg/mL concentration range. The calculated values for detection and quantification of favipiravir were 0.12 and 0.37 µg/mL, respectively. The methodology was verified, and the validation parameters results fell within the acceptable range outlined by ICH protocols. Satisfactory result was obtained on adopting optimized protocol in marketed formulation. Hence, this chromatographic methodology is suitable for the regular analysis of favipiravir in various marketed formulations.Keywords
This publication has 16 references indexed in Scilit:
- New Analytical Methods for the Determination of New Anti-Viral Drug Favipiravir: A Potential Therapeutic Drug Against Covid-19 Virus, in Bulk and Dosage FormsPharmaceutical Chemistry Journal, 2023
- Menthol-assisted homogenous liquid-liquid microextraction for HPLC/UV determination of favipiravir as an antiviral for COVID-19 in human plasmaJournal of Chromatography B, 2021
- A novel stability-indicating HPLC-DAD method for determination of favipiravir, a potential antiviral drug for COVID-19 treatment; application to degradation kinetic studies and in-vitro dissolution profilingMicrochemical Journal, 2021
- Green micellar solvent-free HPLC and spectrofluorimetric determination of favipiravir as one of COVID-19 antiviral regimensMicrochemical Journal, 2021
- HPLC-UV method for quantification of favipiravir in pharmaceutical formulationsActa Chromatographica, 2021
- Experimental design approach for development of spectrofluorimetric method for determination of favipiravir; a potential therapeutic agent against COVID-19 virus: Application to spiked human plasmaSpectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2021
- Favipiravir: A new and emerging antiviral option in COVID-19Medical Journal Armed Forces India, 2020
- Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymeraseProceedings of the Japan Academy, Series B, 2017
- Favipiravir (T-705), a novel viral RNA polymerase inhibitorAntiviral Research, 2013
- International Conference of Harmonization ICH Harmonized Tripartite Guideline2012